Avaí Bio will present clinical data on an encapsulated cell therapy designed to restore circulating α-Klotho, a protein implicated in aging and metabolic regulation. The approach uses Austrianova's Cell-in-a-Box technology to sustain Klotho production, addressing a mechanism that declines with age and correlates with multiple age-related pathologies.
Key Points
- Encapsulated cells produce α-Klotho protein sustainably
- Targets restoration of declining longevity protein levels
- Addresses aging and age-related metabolic dysfunction
Longevity Analysis
Klotho depletion is recognized as a hallmark of aging, affecting mineral metabolism, vascular function, and cellular stress resistance. A sustained delivery system that maintains circulating Klotho levels addresses one of the primary mechanisms underlying age-related decline across multiple organ systems. This approach represents a direct intervention on a pathway known to influence lifespan and healthspan in preclinical models, particularly relevant for individuals with metabolic dysfunction, vascular compromise, or accelerated aging phenotypes.
Original published by LT Wire.